Compare ATGL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | ALXO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 172.8M |
| IPO Year | 2023 | 2020 |
| Metric | ATGL | ALXO |
|---|---|---|
| Price | $8.90 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 102.1K | ★ 1.1M |
| Earning Date | 01-27-2027 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.97 | $0.86 |
| 52 Week High | $50.00 | $2.66 |
| Indicator | ATGL | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 38.82 |
| Support Level | $7.24 | $0.86 |
| Resistance Level | $11.20 | $1.34 |
| Average True Range (ATR) | 0.83 | 0.15 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 29.46 | 19.23 |
Alpha Technology Group Ltd is a Hong Kong-based AI company. Its business focuses on two main directions: building Exclusive Large Language Model solutions and developing AI Agents. The group specializes in creating Exclusive Large Language Models (LLMs) and bespoke AI platforms. These solutions serve as custom AI brains, enabling enterprises to harness their data for strategic decision-making and operational performance. It guides companies of all sizes through digital transformation with scalable, AI-driven solutions that are ESG-sustainable and designed for long-term growth. The cutting-edge offerings, AlphaClaw AI Agents and the AlphaClaw AI Agent Marketplace to empower organizations across diverse industries to optimize operations, automate workflows, and unlock data-driven insights.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.